Figure 2.

Role of HLA-DQ8 in insulin B(9–23)-specific response in a type 1 diabetic patient. A total of 10⁵ T lymphocytes from short-term cell lines of B(9–23)-treated PBMCs from type 1 diabetic patient P2, homozygous for HLA-DR4 (DRB1*0402/0405) and DQ8 (DQB1*0302), were treated in the presence or absence of 20 μg/ml anti-DQ or anti-DR blocking antibody. These antibodies were added to stimulator autologous PBMCs 30 minutes before responder T cells were added. Cells were cultured for 5 days during which each well was pulsed with [³H]thymidine for the final 18–20 hours and the amount of incorporated radioactivity was counted. Isotype control antibody had no significant effect on proliferation. Values are the mean cpm ± SEM of triplicate cultures from one experiment representative of three experiments.